Caribou Biosciences receives FDA IND clearance for CB-011, allogeneic anti-BCMA CAR-T therapy for multiple myeloma

Caribou Biosciences, Inc.

CB-011 is a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking.
CaMMouflage Phase 1 trial is an open-label, multicenter study evaluating CB-011 in relapsed/refractory multiple myeloma.
Patient enrollment at dose level 1 (50x10^6 CAR-T cells) expected to begin in early 2023.
CB-011 uses Cas12a chRDNA edits: anti-BCMA CAR insertion, TRAC KO, and B2M-HLA-E fusion for immune cloaking.
This is Caribou's second allogeneic CAR-T to enter clinic, following CB-010 (anti-CD19, PD-1 KO) in ANTLER trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.